Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma, Follicular × Tacrolimus × Clear all

Phase

Phase 2 32 Phase 1/2 3 Phase 1 3 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Lymphedema 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia 1 Graft vs Host Disease 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 3 fludarabine phosphate 2 Etoposide 2 Cyclophosphamide 2 umbralisib 1 ublituximab 1 remdesivir 1 fludarabine 1 epratuzumab 1 aldesleukin 1 Whole-Body Irradiation 1 UE2343 1 Transplantation, Homologous 1 Transplantation, Autologous 1 Thiotepa 1 Therapeutics 1 Tacrolimus 1 Standard of Care 1 Radiotherapy 1 Radioimmunodetection 1 Methotrexate 1 Melphalan 1 Hydrochlorothiazide 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Drug Therapy 1 Dosage Forms 1 Carmustine 1 Carboplatin 1 COVID-19 Serotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00096460 2023-01-05

BMT CTN 0202

Medical College of Wisconsin

Phase 2/3 Terminated

30 enrolled 5 charts

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡